Evaluation of the therapeutic effect of platinib on RET mutated thyroid cancer

Platinib is a highly selective inhibitor targeting RET gene mutations. Judging from clinical trial data, the therapeutic effect of platinib on RET mutated thyroid cancer is impressive. In related studies, platinib's overall response rate (ORRORR span>) reached 60%, and nearly 80% of responding patients lasted more than 6 months. For those patients with RETmutated MTC who have not received other treatments, the ORR of platinib is as high as 66%, and the duration of response is also satisfactory. These data strongly demonstrate the effectiveness of platinib in the treatment of RET mutated thyroid cancer.

Platinib's high selectivity is a major advantage of its treatment ofRET mutated thyroid cancer. Because Platinib can precisely act on the RET receptor without affecting other normal cells, it not only reduces the proliferation and spread of cancer cells, but also reduces the toxic side effects on normal tissues. This high selectivity not only improves the safety of treatment, but also helps improve patients' quality of life.

Platinib’s oral delivery method also brings convenience to patients. Compared with other anti-cancer drugs that require intravenous injection, the oral dosage form of Platinib allows patients to easily complete treatment at home without frequent trips to the hospital. This convenience undoubtedly reduces the patient's psychological burden and improves treatment compliance.

It is worth noting that although platinib has a significant therapeutic effect on RET mutated thyroid cancer, it is not suitable for all patients with thyroid cancer. Before using platinib, patients need to undergo genetic testing to confirm the presence of RET gene mutations. Only for those patients with positive RET mutations, platinib can exert the best therapeutic effect.